Clinical trials: Empagliflozin
Lupus Nephritis (LN)
The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population
Systemic lupus erythematosis (SLE) is a chronic, most probably auto-immune multisystem disease marked by relapsing-remitting course and the formation of a range of autoantibodies.
- Trial name
- NCT07700940
- Testing
- Empagliflozin (25 Mg Tab) along with standard medical therapy
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Ahmed Yehia Ismail
Type2 Diabetes, Heart Failure With Preserved Ejection Fraction
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and…
- Trial name
- NCT05057806
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Pre-Heart Failure, Hypertension
Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for…
- Trial name
- NCT06055452
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- China National Center for Cardiovascular Diseases
Type 2 Diabetes Mellitus, Dyslipidemia
Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia
The purpose of this study is to evaluate the efficacy and safety of Berlim 25/10 association in the treatment of type 2 diabetes mellitus and dyslipidemia.
- Trial name
- NCT04603508
- Testing
- BERLIM 25/10 association, EMPAGLIFLOZIN, ROSUVASTATIN CALCIUM
- Volunteers
- 240 people
- Sponsor
- EMS
T2DM, Diabete Type 2
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.
- Conditions
- T2DM, Diabete Type 2, DM
- Trial name
- NCT07093476
- Testing
- Metformin, Alogliptin, empagliflozin
- Where
- South Korea
- Volunteers
- 171 people
- Sponsor
- Celltrion
Type 2 Diabetes Mellitus
Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus
The main pathogenesis of type 2 diabetes mellitus is insulin resistance and insufficient secretion of insulin by pancreatic beta cells.
- Trial name
- NCT04014192
- Testing
- Dapagliflozin, Empagliflozin, Canagliflozin
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Transplant; Failure, Heart, Cardiac Allograft Vasculopathy
Impact of SGLT2 Inhibitors in Heart Transplant Recipients
The goal of this clinical trial is to test if SGLT2 inhibitors could prevent or delay the development of Cardiac Allograft Vasculopathy (CAV) post-heart transplantation (TxC).
- Conditions
- Transplant; Failure, Heart, Cardiac Allograft Vasculopathy, Rejection Heart Transplant
- Trial name
- NCT06147271
- Testing
- SGLT2i
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Universidade Federal do Ceara
Diabetes Mellitus, Type 2, Coronary Artery Disease
POST-CABGDM: Empagliflozin in Perioperative CABG
Introduction: Diabetes Mellitus (DM) is a condition known to be associated with coronary artery disease (CAD) and its role as promoter of atherosclerosis is well stablished.
- Conditions
- Diabetes Mellitus, Type 2, Coronary Artery Disease, Coronary Artery Bypass Surgery, Acute Kidney Injury
- Trial name
- POST-CABGDM (NCT04523064)
- Testing
- Empagliflozin 25 MG
- Where
- Brazil
- Volunteers
- 155 people
- Sponsor
- University of Sao Paulo General Hospital
Type 2 Diabetes Mellitus
Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen
In the treatment of type 2 diabetes (T2D), the number of patients requiring combination therapy of oral antidiabetic agents (OADs) is more than 70%.
- Trial name
- NCT04013581
- Testing
- TZD group, SGLT-2 group
- Where
- South Korea
- Volunteers
- 121 people
- Sponsor
- Yonsei University
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disease, often compounded by obesity, that leads to serious long-term health complications.
- Trial name
- NCT07728318
- Testing
- Tirzepatide + Standard Therapy (Intervention Group), Standard Oral Antidiabetic Drugs (OADs)
- Volunteers
- 52 people
- Sponsor
- Akhtar Saeed Medical and Dental College
Hypertension, Cardiovascular Diseases
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce CVD events, including incident HF. SGLT2 is a glucose transport protein in the kidneys. Inhibition of this protein results in glucosuria and lower serum blood sugar.
- Trial name
- NCT06507657
- Testing
- empagliflozin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Minnesota
Type 1 Diabetes
Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes
The goal of this 26-week multicenter, randomized, parallel, placebo-controlled trial is to test the effectiveness of empagliflozin use in conjunction with automated insulin delivery (AID) to improve glucose control in individuals…
- Trial name
- NCT06021145
- Testing
- Empagliflozin
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Healthy
Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers
The aim of the trial is to assess the relative bioavailability of fixed dose combination tablets of Empagliflozin and metformin compared to the administration of single tablets (Empagliflozin and metformin ) in Chinese subjects.
- Trial name
- NCT02102932
- Testing
- 5 mg empagliflozin/850 mg metformin FDC, 12.5 mg empagliflozin, 850 mg metformin
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Severe Aortic Valve Stenosis
A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis
This study will include patients with severe degenerative aortic stenosis (AS) who meet the inclusion criteria and voluntarily participate (planned to undergo TAVI), as well as patients with aortic stenosis who have not undergone…
- Trial name
- NCT07335900
- Testing
- Transcatheter Aortic Valve Implantation, Optimal medication treatment
- Where
- China
- Volunteers
- 25 people
- Sponsor
- RenJi Hospital
Genetic Polymorphisms, Heart Failure
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown further reductions in heart failure hospitalization, cardiovascular events, and mortality, especially for heart failure patients.
- Trial name
- NCT06201000
- Testing
- SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- October 6 University
Diabetes Mellitus, Type 2, Diastolic Dysfunction
Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics
The purpose of the EmDia trial is to compare the effects of empagliflozin with placebo in addition to standard diabetic treatment or dietetic treatment on cardiac diastolic function in patients with type 2 Diabetes mellitus.
- Trial name
- EmDia (NCT02932436)
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 144 people
- Sponsor
- Johannes Gutenberg University Mainz
Healthy
Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects
The objective of this study is to demonstrate that BI 10773 does not prolong the QT(c) interval more than placebo
- Trial name
- NCT01195675
- Testing
- BI 10773 (low), Moxifloxacin, BI 10773 (high)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Cirrhosis, Liver Failure
Empagliflozin in Patients With Cirrhosis and Ascites
A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites.
- Trial name
- EMPA Liver (NCT05726032)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Diabetes Mellitus, Type 2
Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to integrate the post-marketing surveillances data (Specified use-results surveys on long-term treatment) of the 6 SGLT2 inhibitors approved or applied in Japan and to evaluate the safety and efficacy…
- Trial name
- NCT02284269
- Testing
- SGLT2 Inhibitors
- Volunteers
- 18,000 people
- Sponsor
- Pharmaceuticals and Medical Devices Agency, Japan
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic…
- Trial name
- NCT01167881
- Testing
- BI 10773, Glimepiride
- Where
- 182 sites in United States, Argentina and 21 more
- Volunteers
- 1,549 people
- Sponsor
- Boehringer Ingelheim